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Key Points
Question
What is the association between treatment guided by ambulatory hemodynamic monitoring and clinical outcomes in
patients with heart failure?
Findings
In this matched cohort study, 1087 patients receiving a wireless pulmonary artery pressure sensor had a significantly
lower rate of heart failure hospitalization at 12 months than a cohort of concurrently treated, propensity-matched
control patients.
Meaning
In patients with chronic heart failure, ambulatory hemodynamic monitoring is associated with reduced rates of heart
failure hospitalization.

Abstract
Importance
In a randomized clinical trial, heart failure (HF) hospitalizations were lower in patients managed with guidance from
an implantable pulmonary artery pressure sensor compared with usual care. It remains unclear if ambulatory
monitoring could also improve long-term clinical outcomes in real-world practice.
Objective

To determine the association between ambulatory hemodynamic monitoring and rates of HF hospitalization at 12
months in clinical practice.
Design, Setting, and Participants
This matched cohort study of Medicare beneficiaries used claims data collected between June 1, 2014, and March 31,
2016. Medicare patients who received implants of a pulmonary artery pressure sensor were identified from the 100%
Medicare claims database. Each patient who received an implant was matched to a control patient by demographic
features, history of HF hospitalization, and number of all-cause hospitalizations. Propensity scoring based on
comorbidities (arrhythmia, hypertension, diabetes, pulmonary disease, and renal disease) was used for additional
matching. Data analysis was completed from July 2017 through January 2019.
Exposures
Implantable pulmonary artery pressure monitoring system.
Main Outcomes and Measures
The rates of HF hospitalization were compared using the Andersen-Gill method. Days lost owing to events were
compared using a nonparametric bootstrap method.
Results
The study cohort consisted of 1087 patients who received an implantable pulmonary artery pressure sensors and 1087
matched control patients. The treatment and control cohorts were well matched by age (mean [SD], 72.7 [10.2] years
vs 72.9 [10.1] years) and sex (381 of 1087 female patients [35.1%] in each group), medical history, comorbidities,
and timing of preimplant HF hospitalization. At 12 months postimplant, 616 HF hospitalizations occurred in the
treatment cohort compared with 784 HF hospitalizations in the control cohort. The rate of HF hospitalization was
lower in the treatment cohort at 12 months postimplant (hazard ratio [HR], 0.76 [95% CI, 0.65-0.89]; P < .001). The
percentage of days lost to HF hospitalizations or death were lower in the treatment group (HR, 0.73 [95% CI, 0.640.84]; P < .001) and the percentage of days lost owing to all-cause hospitalization or death were also lower (HR, 0.77
[95% CI, 0.68-0.88]; P < .001).
Conclusions and Relevance
Patients with HF who were implanted with a pulmonary artery pressure sensor had lower rates of HF hospitalization
than matched controls and spent more time alive out of hospital. Ambulatory hemodynamic monitoring may improve
outcomes in patients with chronic HF.

Introduction
Despite therapeutic advances, chronic heart failure (HF) remains a progressive disease, with advanced stages
characterized by worsening symptoms, recurrent hospitalizations, and eventual death. Regardless of ejection fraction,
elevations of intracardiac and pulmonary artery pressures (PAP) are a defining hemodynamic disturbance in the
progression of HF. Because pressure elevations precede clinical signs and symptoms in statistically and clinically
significant ways,1,2,3 longitudinal monitoring of central hemodynamics can facilitate timely interventions to reduce
pressures, improve symptoms, and avoid costly hospitalizations.
Clinical trials of ambulatory hemodynamic monitoring systems have shown that lower cardiac-filling pressures are
associated with lower rates of HF hospitalization3,4 and mortality.5 Moreover, real-world experience with an
approved, implantable PAP sensor has shown that clinically significant reductions in PAP6 and reduced rates of HF7
are associated with sensor implants.
Uncertainty remains about the utility of ambulatory hemodynamic monitoring and its association with long-term
outcomes.8 We hypothesized that improved hemodynamic management could reduce hospitalizations and increase
days alive out of hospital. We therefore analyzed Medicare claims data to explore rates of HF hospitalization and
death at 12 months in a cohort of patients implanted with a PAP sensor compared with matched control patients
without a sensor.

Methods
Data Source
This matched cohort study using Centers for Medicare and Medicaid Services (CMS) administrative claims data from
the Standard Analytic File was designed to evaluate clinical outcomes in beneficiaries of fee-for-service Medicare
programs who received a PAP sensor implant after US Food and Drug Administration approval of the device for
commercial use (from June 1, 2014, onward) compared with matched control patients who did not receive a sensor.
Claims data include Part A inpatient claims, Part B outpatient claims, and the associated denominator files.9 Inpatient
and outpatient files contain institutional claims with International Classification of Diseases, Ninth Revision, Clinical
Modification and Tenth Revision, Clinical Modification diagnosis codes, procedure codes, and reimbursement
associated with inpatient stays or ambulatory visits. The denominator files include unique deidentified patient
identification numbers, age, sex, geographic location, race/ethnicity, date of death, and information about program
eligibility and Medicare insurance enrollment.
The study was a retrospective analysis of a deidentified database and thus exempt from institutional review board
approval. Deidentified health information can be used without authorization or any other permission specified in the
Health Insurance Portability and Accountability Act Privacy Rule, and this study was therefore exempt from
informed consent procedures.
Identification of the Treatment Cohort
We identified patients implanted with a PAP sensor using inpatient claims associated with the procedure codes 38.26,
02HQ30Z, or 02HR30Z and outpatient claims associated with Current Procedural Terminology codes C9741 and
C2624 (eTable 1 in the Supplement). Because Medicare data were available through March 31, 2017, only patients
who received implants on or prior to March 31, 2016, were included, to ensure a minimum of 12 months of potential
follow-up time. The cohort was limited to patients with continuous, fee-for-service Medicare insurance enrollment
(Medicare parts A and B) for at least 12 months before and after sensor implant. Health maintenance organization
paid claims are excluded from the CMS data set; accordingly, health maintenance organization–insured patients were
excluded to avoid incomplete data. The claims data extraction and statistical analyses were conducted using RStudio
version 1.0.143 (R Consortium) and R version 3.4.0 (R Foundation for Statistical Computing).
Identification of Matched Controls
Using the full Medicare data set, a matched control was identified for each patient that received the CardioMEMS
hemodynamic sensor (Abbott). Potential control patients were first identified based on the presence of at least 1 HF
hospitalization between July 1, 2013, and March 31, 2016, yielding a population of 1.5 million patients with HF. The
date of implant for each patient undergoing PAP sensor implant was used as an anchor point to identify the matched
control patients. For example, if the patient in the treatment cohort was implanted with a sensor on January 1, 2016,
this date served as a temporal reference point to find a matched control patient with an identical clinical profile in the
12 months prior to that date. All patient characteristics used for matching were retrieved in the 12 months preceding
the anchor date.
A stepwise, iterative algorithm was then used to identify the closest match between a patient who received an implant
and a patient who did not receive an implant. In each iterative run of the algorithm, matched pairs were withdrawn
from further consideration. After 3 steps of the iterative algorithm, matched controls were identified for 1087 of the
1185 patients who received implants. An identical match was defined in each iterative run based on sequential
matching of demographic attributes (sex, race, history of implantable cardioverter defibrillator or cardiac
resynchronization therapy implant, end-stage renal disease status, and age within 5 years), then comorbidities
(diabetes, hypertension, renal disorders, pulmonary disorders, and arrhythmia), followed by the closest propensity
score (derived using logistic regression). Additionally, patients were matched if they incurred an identical number of
HF and non-HF hospitalizations and if the timing of each HF hospitalization was within 4 months. This method was
used to provide a close approximation of HF severity between patients who received implants and control patients.
Finally, after the matching procedure, we compared the severity of HF hospitalization using length of stay for each
HF hospitalization and cumulative number of hospitalized days per patient.

Comorbidities for each patient were determined from outpatient and inpatient encounters in the 12 months prior to the
anchoring point. Detailed diagnoses codes for the comorbidities of diabetes, hypertension, renal disorders, pulmonary
disorders, and arrhythmia10,11 are provided in eTable 2 in the Supplement. A hospitalization was deemed to be HFassociated based on the presence of diagnoses codes attributed to HF as defined by CMS methods (eTable 3 in the
Supplement).12 In the treatment cohort, we identified preimplant HF events as those for which a diagnosis code of
HF was recorded anywhere in the hospitalization claim; after sensor implant, we used only HF events that were the
primary reason for admission. In the control cohort, we counted all HF events in which an HF diagnosis code was the
primary reason for hospitalization to ensure that this cohort included only patients who met the approved indication
(namely, an HF hospitalization in the preceding 12 months). For both treatment and control cohorts, all other
hospitalizations that did not have a HF diagnosis were classified as non-HF events.
Statistical Analysis
The primary outcomes were HF hospitalization and cumulative days lost because of HF hospitalization or death at the
12 months after the anchor date. Rates of HF hospitalization were compared using the Andersen-Gill model for
recurrent events with censoring at the time of death, ventricular assist device (VAD) implant, or heart transplant.
Heart transplant or VAD implantation was identified using a Medicare Severity Diagnosis Related Groups assignment
of 001 or 002 (heart transplant or implant of heart assist system without major comorbidity or complication). A robust
variance estimate was used in the Andersen-Gill model to account for possible within-participant dependence from
recurrent hospitalizations. Results in relevant subgroups defined by age, sex, comorbidities, and history of
implantable cardioverter defibrillator and/or cardiac resynchronization therapy implant were also analyzed. Crude
mortality rates were compared between treatment and control populations using Kaplan-Meier survival analysis. The
comparison of the days lost owing to events was performed using a nonparametric bootstrap model; events were
defined as HF hospitalization, all-cause hospitalization, and death.
Sensitivity Analysis
The primary outcomes were assessed in a 1:1 matched cohort based on the algorithm described in eFigure 1 in the
Supplement. The matching algorithm was designed to minimize the mean difference between hospitalization timing
within pairs of patients in the treatment group and control patients. A sensitivity analysis was conducted to
characterize the variability in outcomes using a nonparametric bootstrap model using a 1:X matched cohort that
satisfied the matching criteria of the algorithm. To assess for variations in care provided at implanting centers vs
nonimplanting centers, we further analyzed outcomes in a subgroup of treatment-control pairs that received inpatient
care at the same hospital, as determined by the 6-digit Medicare provider identification code.
All tests were 2-tailed, and P values of .05 or less were considered significant. Data analysis was completed from
July 2017 to January 2019. Claims data were extracted with RStudio version 1.0.143 (RStudio Inc) and R version
3.4.0 (R Foundation for Statistical Computing), and the statistical analyses were conducted using R version 3.1.1
(Revolution Analytics).

Results
Of 1451 Medicare patients who underwent a PAP sensor implant procedure from June 1, 2014, to March 31, 2016,
and had a hospitalization in the previous 12 months, 107 patients were excluded owing to discontinuous enrollment in
Medicare insurance and 159 owing to their health maintenance organization insurance recipient status or receiving a
VAD implant prior to sensor implant (eFigure 2 in the Supplement). The remaining 1185 patients were continuously
enrolled in Medicare and had available data regarding clinical outcomes for at least 12 months before and after
implantation. Of the 1.5 million potential control patients with HF from the full Medicare data set, 1087 were
matched to this treatment cohort. All outcomes are reported in these 1087 matched treatment and control pairs.
Baseline Patient Characteristics
The patient characteristics for the 2 groups are reported in Table 1. The treatment and control cohorts were well
matched for age (mean [SD], 72.7 [10.2] years vs 72.9 [10.1] years), demographic characteristics, and comorbidity
profiles (Table 1). Chronic ischemic heart disease was not a matching criteria yet was similarly prevalent between the
treatment and control cohorts (785 of 1087 [72.2%] vs 761 of 1087 [70.0%]; P = .26). Propensity score density plots

show close matching between cohorts based on the 5 comorbidities of interest used in the matching algorithm
(eFigure 3 in the Supplement). Standardized mean difference estimates were lower than 10% for all match
parameters.
The Elixhauser Comorbidity Index variables consist of 30 conditions. Although 5 comorbidities of interest were used
to match control patients, there were no statistical differences between the treatment and control cohorts among the
remaining 25 comorbid conditions (eTable 4 in the Supplement).
Heart Failure Characteristics
Heart failure hospitalizations were matched temporally for the 2 groups. Figure 1 represents the time series of the
heart failure hospitalizations in the 12 months prior to the anchor point for treatment and control pairs. These
recurrent events were compared between the 2 groups using the Andersen-Gill model (hazard ratio [HR], 0.99 [95%
CI, 0.95-1.05]; P = .97), showing a closely matched temporal profile. The mean (SD) difference between
hospitalization timing was 39.5 (38.5) days, and the mean (SD) cumulative days in hospital for the year prior to
implant were 12.7 (12.7) days per patient for the treatment cohort and 11.4 (11.4) days per patient for the control
group.
Clinical Outcomes
Over the 12-month follow-up period, the 1087 treatment cohort patients had 616 HF hospitalizations, 241 deaths, and
20 VAD implants or heart transplants; over the same period, the control cohort had 784 HF hospitalizations, 325
deaths, and 13 VAD implants or heart transplants. The clinical events over 12 months’ follow-up are reported in
Table 2; follow-up was censored at death, VAD implant, or heart transplant. The mean (SD) length of hospital stay
was 6.6 (6.5) days in the treatment cohort and 6.5 (5.8) days in the control cohort (P = .70). The mean (SD) total time
in hospital for HF was 3.7 (9.5) days per patient for the treatment group and 4.4 (10.3) days per patient for the control
group.
Hospitalization for HF or death occurred in 469 patients (43.1%) in the treatment cohort and 597 (54.9%) of the
control cohort. The percentage of days lost owing to HF hospitalization or death was reduced in the treatment cohort
(13.7% [95% CI, 12.1%-15.3%) compared with the control cohort (18.8% [95% CI, 16.9%-20.7%]; risk ratio, 0.73
[95% CI, 0.63-0.85]; P < .001). The treatment cohort lost a mean (SD) of 50.0 (98.3) days per year, vs 68.4 (116.0)
days per year lost in the control cohort (Table 3).
Heart failure hospitalizations occurred at a lower rate in the treatment cohort than the control cohort (0.65 vs 0.88;
HR, 0.76 [95% CI, 0.65-0.89]; P < .001). The cumulative incidence of HF hospitalization is shown in Figure 2A. The
mortality rate at 12 months was also significantly lower in the treatment cohort than the control cohort (0.23 deaths
per year vs 0.30 deaths per year; HR, 0.70 [95% CI, 0.59-0.83]; P < .001; Table 3). The Kaplan-Meier survival curve
for all-cause mortality is shown in Figure 2B. A combined end point of heart failure hospitalization and mortality was
lower in the treatment cohort than in the control cohort (0.90 events per patient per year vs 1.23 events per patient per
year; HR, 0.73 [95% CI, 0.64-0.84]; P < .001). Days lost to death (46.2 vs 64.2 days; absolute difference, −17.9 days;
HR, 0.72 [95% CI, 0.62-0.84]; P < .001), HF hospitalization or death (50.0 vs 68.4 days; absolute difference, −18.5
days; HR, 0.73 [95% CI, 0.63-0.85]; P < .001), and all-cause hospitalization or death (56.9 vs 74.5 days; absolute
difference, −17.5 days; HR, 0.77 [95% CI, 0.68-0.88]; P < .001) were significantly lower in the treatment cohort than
the control cohort. Sensor implant was associated with a difference of 17 more days alive and out of the hospital.
The relative reduction in HF hospitalization, mortality, and the combined end point of HF hospitalization and death
was consistent across subgroups defined by age (<75 years and ≥75 years), sex, comorbidities, and history of
implantable cardioverter defibrillator and/or cardiac resynchronization therapy implant (eFigure 4 in the Supplement).
Sensitivity Analysis
The primary analysis was based on a 1:1 matched cohort fulfilling all prespecified match criteria and minimizing the
mean difference between hospitalization timing. To characterize variation in clinical outcomes, we used a
nonparametric bootstrap model based on data from 41 347 control patients who were matched to the 1087 patients
who received implants. The HF hospitalization rate of the control cohort was 0.93 (interquartile range [IQR], 0.900.95), and relative risk for HF hospitalization was 0.70 (IQR, 0.68-0.72, P < .001). The mortality rate of the control

cohort was 0.31 (IQR, 0.30-0.32). The relative risk for mortality was 0.71 (IQR, 0.69-0.73; P < .001). eFigure 5 in the
Supplement shows the cumulative probability distribution for HF hospitalization and mortality outcomes from the
model (× 10 000).
Because implanting centers may have unmeasured, systemic differences from nonimplanting centers that could
influence patient outcomes, we further compared outcomes of treatment-control pairs that had received care at the
same implanting center. The patients in the treatment arm were implanted at 255 unique facilities.13 From the
treatment arm, 774 patients were matched with 8973 control patients treated at the same centers. The HF
hospitalization rate in this subgroup of the treatment cohort was lower than that of control patients (0.52 vs 0.81
[IQR, 0.80-0.84]; P < .001; relative risk, 0.64 [IQR, 0.63-0.66]; P < .001). The mortality rate of this subset of patients
with implants was also lower than the matched control patients (0.22 vs 0.28 [IQR, 0.27-0.29]; relative risk, 0.76
[IQR, 0.74-0.79]; P < .01]). The cumulative probability distribution for HF hospitalization and mortality outcomes
from the model (× 10 000) is shown in eFigure 6 in the Supplement.

Discussion
In this retrospective Medicare claims analysis, we observed lower rates of HF hospitalization among patients
implanted with a PAP sensor compared with a contemporary cohort of propensity-matched controls. We also
observed a lower rate of all-cause mortality among patients implanted with a PAP sensor, although this finding is
considered exploratory because claims data may be insufficiently detailed to adjust adequately for HF severity. This
study substantially extends the findings of a prior analysis of ambulatory hemodynamic monitoring in a smaller
population of Medicare recipients that did not have a separate control cohort.7
We used a novel matching algorithm to construct a propensity-matched control cohort that allows for a
pseudorandomized comparison. Treatment and control cohorts were matched for 5 relevant comorbidities, and in this
large patient sample, the matching algorithm yielded a similar comorbidity profile for diverse conditions not specified
by the algorithm. Bootstrap analysis shows that the resulting differences in clinical outcomes between treatment and
control cohorts are robust and relatively insensitive to the choice of matched control patient. Further analysis of
treatment-control pairs that had received care at the same implanting center indicates that outcome differences
between treatment and control cohorts could be in part because of practice variations. After accounting for these
differences, however, the clinical outcomes remain significantly different in all settings.
The reduced rates of HF hospitalization and mortality associated with sensor implant in this study are similar to the
outcomes of the randomized CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in
New York Heart Association Functional Class III Heart Failure Patients (CHAMPION) trial.4,14 Whereas differences
in HF hospitalization rates became evident at 3 months in CHAMPION, we observed lowered HF hospitalization
rates as early as 1 month after sensor implant. One potential explanation for this difference is that, in CHAMPION,
both arms underwent right-heart catheterization. Knowledge of baseline hemodynamic data could favorably influence
treatment of control patients and thereby delay the benefit of ambulatory pressure monitoring. Additionally, the
patients who received PAP sensors in the Medicare population in this study are significantly older, with a higher
proportion of female patients than in CHAMPION. Real-world experience with the implantable PAP monitoring
system in a demographically similar population showed higher baseline PAP and greater pressure changes than in
CHAMPION.6
The composite outcome of days alive and out of hospital is an important, patient-centered measure that summarizes
the treatment effect of an intervention on both hospitalization and mortality.15 Compared with conventional time-toevent end points, this measure accounts for multiple events occurring during follow-up. In a prospectively
randomized study of a structured remote patient management intervention vs usual care,16,17 the telemedicine
intervention resulted in a mean difference of 6 days per year lost owing to cardiovascular hospitalization or death.
This difference was deemed to be clinically meaningful for patients, physicians, and payers. In the present study,
implant of a hemodynamic sensor was associated with 17 fewer days lost for all-cause hospitalization or death within
the year of follow-up.
Episodes of worsening HF requiring intensification of therapy are associated with increased risks of hospital
readmission and death.18,19 Remote monitoring of nonhemodynamic clinical surrogates, including body weight,20,21
intrathoracic impedance,22 natriuretic peptides,23 and device-based telemonitoring16,24,25 have produced mixed
results in prospective randomized clinical trials. Although CHAMPION demonstrated possible improved survival
4

outcomes, it was not statistically powered to assess mortality.4 A prospective, randomized study (HemodynamicGuided Management of Heart Failure [GUIDE-HF]; NCT03387813) is underway to assess the effect of ambulatory
PAP monitoring on long-term survival and hospitalization in chronic HF, coupled with quality of life and functional
capacity.
Limitations
The limitations of the study are those inherent to an observational analysis using Medicare claims data. Important
clinical information, such as ejection fraction, natriuretic peptide levels, and renal function, are not known. Medical
therapy, indications for PAP sensor implant, and complications of sensor implant are similarly not available. Residual
confounding by unmeasured covariates remains possible. We are unable to assess medication changes or link
outcomes to PAP sensor data; thus, we cannot definitely exclude the possibilities that selection bias or heightened
involvement of the health care team after sensor implant, rather than interventions triggered by hemodynamic data
per se, are partially responsible for differences in outcomes. Finally, CMS methods were used to define the study end
points, and clinical events were not formally adjudicated. We attempted to reduce the inherent limitations of an
observational, claims-based design by cohort matching based on demographic factors, comorbidity profiles, and HF
hospitalization frequency and timing. While randomization remains the evidentiary gold standard for experimental
design, the novel matching procedure allows for a more rigorous outcomes comparison between cohorts. Several
pitfalls of using big data based on claims reporting are reduced using this method.26,27

Conclusions
Hemodynamic, guided HF management was associated with improved long-term clinical outcomes, including
significant reduction in days lost owing to hospitalization or death. These findings are being prospectively evaluated
in an ongoing randomized clinical trial (GUIDE-HF).

Notes

Supplement.

eTable 1. Billing Procedure Codes Used to Identify PAP Sensor Implants
eTable 2. Diagnoses Codes Used to Identify Comorbidities
eTable 3. Billing Codes Used to Identify HF Hospitalization
eTable 4. Baseline Patient Characteristics: All Elixhauser Comorbidities that were not used for Matching
criteria
eFigure 1. Algorithm for Matched Patient Identification
eFigure 2. Patient Cohort Identification
eFigure 3. Propensity score Match comparison
eFigure 4. Clinical outcomes (Heart Failure Hospitalizations and Mortality) in Subgroups of Interest in the
12-months after PA pressure sensor implant
eFigure 5. Distribution of outcomes amongst all matches
eFigure 6. Distribution of outcomes in patients treated at CMEM implanting sites
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Figures and Tables

Table 1.
Patient Characteristics at Baseline
Characteristic

Cohort, No. (%)

P Value

Treatment (n = 1087) Control (n = 1087)
Demographic factors
Age, median (IQR), y

73 (67-80)

74 (67-80)

a
.60

Female

381 (35.1)

381 (35.1)

>.99

White

910 (83.7)

910 (83.7)

>.99

Black

137 (12.6)

137 (12.6)

>.99

Hispanic

11 (1.0)

11 (1.0)

>.99

Asian

13 (1.2)

13 (1.2)

>.99

Other

16 (1.5)

16 (1.5)

>.99

History of ICD or CRT device

494 (45.4)

494 (45.4)

>.99

Arrhythmia

810 (74.5)

824 (75.8)

.52

Hypertension

945 (86.9)

963 (88.6)

.27

Diabetes

577 (53.1)

564 (51.9)

.61

Pulmonary disease

608 (55.9)

638 (58.7)

.21

Renal disease

540 (49.7)

580 (53.4)

.09

1068 (98.3)

>.99

Race/ethnicity

Comorbidities

Without end-stage renal disease 1068 (98.3)

Abbreviations: CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; IQR, interquartile range.
a

P value from Wilcoxon rank sum test; all other P values for all comorbidities χ2 test.

Figure 1.

Time Series of Heart Failure Hospitalizations in the 12 Months Before Pulmonary Artery Pressure Sensor Implant
Data from prior to the pulmonary artery pressure sensor implant include heart failure events (treatment cohort, 2532; control cohort,
2532; P > .99); length of stay per heart failure hospitalization (mean [SD]: treatment cohort, 5.5 [4.9] days; control cohort, 4.9 [4.1]
days; P = .003); time in hospital per patient (mean [SD]: 12.7 [12.7] days; 11.4 [11.4] days; P = .05); and total hospital time (treatment
cohort, 13 857 days; control cohort, 12 442 days; P > .99).

Table 2.
Clinical Outcomes During Follow-up Period
Outcome

Patients, No. (%)
Treatment Cohort (n = 1087) Control Cohort (n = 1087)

Clinical events
a
Heart failure hospitalization, No. of events 616

784

Death

241 (22.2)

325 (29.9)

Ventricular assist device or transplant

20 (1.8)

13 (1.2)

Hospitalization for any cause, No. of events 1846

1818

Patients with ≥1 clinical event
a
Heart failure hospitalization

345 (31.7)

422 (38.8)

a
Heart failure hospitalization or death

469 (43.1)

597 (54.9)

Hospitalization for any cause

695 (63.9)

695 (63.9)

Hospitalization for any cause or death

735 (67.6)

783 (72.0)

aInpatient heart failure hospitalization; identified in primary diagnosis code per Centers for Medicare and Medicaid Services.

Table 3.
Comparative Effectiveness of Pulmonary Artery Pressure Sensor-Based Management on Clinical Event
Rates and Days Lost
Outcome

Mean (SD)

a
Hazard Ratio or Risk
b
Ratio (95% CI)

Absolute

P

Difference, d

Value

Treatment Cohort

Control Cohort

(n = 1087)

(n = 1087)

0.65

0.88

0.76 (0.65-0.89)

NA

<.001

Mortality, death per y

0.23

0.30

0.70 (0.59-0.83)

NA

<.001

Heart failure or death
a
Days lost per patient

0.90

1.23

0.73 (0.64-0.84)

NA

<.001

To death

46.2

64.2

0.72 (0.62-0.84)

−17.9

<.001

To heart failure

50.0

68.4

0.73 (0.63-0.85)

−18.5

<.001

56.9

74.5

0.77 (0.68-0.88)

−17.5

<.001

Clinical event rates per
patient per y
Heart failure
c
hospitalization

hospitalization or death
To any-cause
hospitalization or death

Abbreviation: NA, not applicable.
a

Hazard ratios, 95% CIs, and P values for events were derived using the Andersen-Gill extension of the Cox proportional hazards
model. Mortality rates are the Kaplan-Meier estimates of mortality.
b
Mean, 95% CI, hazard ratio, and P values for comparing days lost were derived from nonparametric bootstrap model.
c
Inpatient heart failure hospitalization; identified in primary diagnosis code per Centers for Medicare and Medicaid Services.

Figure 2.

Open in a separate window
Cumulative Events After Pulmonary Artery Pressure (PAP) Sensor Implant
A, Heart failure (HF) hospitalizations. B, Deaths. C, Combined heart failure hospitalizations and death.

